These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22719022)

  • 1. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
    Nikolic E; Janzon M; Hauch O; Wallentin L; Henriksson M;
    Eur Heart J; 2013 Jan; 34(3):220-8. PubMed ID: 22719022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
    Chin CT; Mellstrom C; Chua TS; Matchar DB
    Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
    Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
    Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
    Gasche D; Ulle T; Meier B; Greiner RA
    Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
    Molina-Cuadrado E; Mateo-Carrasco H; Nieto-Guindo P; Rodríguez-Gómez P
    Farm Hosp; 2014 Jul; 38(4):266-75. PubMed ID: 25137159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
    Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
    Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
    Theidel U; Asseburg C; Giannitsis E; Katus H
    Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
    Wu B; Tobe RG; Liu Y; He B
    Clin Drug Investig; 2018 Jul; 38(7):621-630. PubMed ID: 29713921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
    Okere AN; Ezendu K; Berthe A; Diaby V
    J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery].
    Zyryanov SK; Belousov DY; Afanasyeva EV; Dumchenko EV
    Ter Arkh; 2016; 88(9):39-49. PubMed ID: 27735912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
    Zhao YJ; Khoo AL; Lin L; Teng M; Wu TS; Chan MY; Lim BP
    Value Health Reg Issues; 2016 May; 9():22-27. PubMed ID: 27881255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
    Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
    Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
    Thi Thu Nguyen T; Van Do D; Mellstrom C; Quang Nguyen T; Manh Pham H; Van Hoang S; Cong Luu T; Le Phuong T
    Adv Ther; 2021 Jul; 38(7):4026-4039. PubMed ID: 34115329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.